natgillin/translations-raw huggingface dataset:
Persons with a known hypersensitivity to cabergoline or any of the excipients should avoid contact with the veterinary medicinal product.
Osobe preosjetljive na kabergolin ili na bilo koju od pomoćnih tvari trebaju izbjegavati kontakt s veterinarsko-medicinskim proizvodom.
The recommended dose is 5.6 mg of cabergoline (corresponding to 5 ml of solution for injection) per animal in one single injection at the day of drying-off after the last milking.
Preporučena doza je 5,6 mg kabergolina (odgovara 5 ml otopine za injekciju) po životinji u jednoj jednokratnoj injekciji na dan zasušivanja nakon zadnje mužnje.
The difference between groups was 13.7% (95% confidence interval 6.4-21%).
Razlika između skupina bila je 13,7% (95% interval pouzdanosti; 6,4-21%).
It acts on dopamine receptors of prolactin producing cells in the pituitary gland suppressing the prolactin production and leading to the inhibition of prolactin secretion dependent process.
Djeluje na dopaminske receptore stanica koje proizvode prolaktin u hipofizi suprimirajući proizvodnju prolaktina i dovodeći do inhibicije procesa ovisnih o lučenju prolaktina.
In a multicentric randomized clinical trial where dairy cows with no intramammary infections at the time of drying-off were administered either Velactis or placebo at the time of drying-off, the incidence of new intramammary infections within 7 days after subsequent calving was significantly lower among udder quarters of cows treated with Velactis (20.5%) as compared to placebo (26.0%).
U multicentričkom randomiziranom kliničkom ispitivanju u kojem je u muznih krava bez intramamarne infekcije u vrijeme zasušivanja primjenjivan Velactis ili placebo u vrijeme zasušivanja, učestalost novih intramamarnih infekcija unutar 7 dana nakon telenja bila je značajno niža u četvrtima vimena krava liječenih Velactisom (20,5%) u usporedbi s placebom (26,0%).
In a randomized and placebo controlled clinical study, reduced discomfort was demonstrated during the first day after drying-off by increasing daily lying time by 143 +/- 17 minutes in Velactis treated animals in comparison with untreated controls.
U randomiziranom i placebom kontroliranom kliničkom ispitivanju pokazalo se smanjenje nelagode tijekom prvog dana nakon zasušivanja koje se manifestiralo produženjem vremena ležanja za 143 +/- 17 minuta u životinja liječenih Velactisom u usporedbi s neliječenim životinjama.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web stranici Europske agencije za lijekove (http://www.ema.europa.eu/).
In a randomized and placebo controlled clinical study Velactis treated cows presented less signs of udder pain in comparison with controls on the first two days after drying-off.
U randomiziranom i placebom kontroliranom kliničkom ispitivanju krave liječene Velactisom pokazivale su manje znakova boli u vimenu u usporedbi s kontrolama u prva dva dana nakon zasušivanja.
At 9 times the recommended dose a decrease in ruminal activity may be observed.
Pri dozama 9 puta većima od preporučene može se uočiti smanjeno preživanje.
In the same study, incidence of milk leakage was significantly lower among Velactis treated animals (2.0%) as compared to placebo treated animals (10.7%).
U istom ispitivanju učestalost curenja mlijeka bila je značajno niža u životinja liječenih Velactisom (2,0%) u usporedbi sa životinjama liječenim placebom (10,7%).
cabergoline
NUSPOJAVE
The recommended dose is 5.6 mg of cabergoline (corresponding to 5 ml of Velactis) per animal in one single injection at the day of drying-off after the last milking.
Preporučena doza je 5,6 mg kabergolina (odgovara 5 ml Velactisa) po životinji u jednoj jednokratnoj injekciji na dan zasušivanja, nakon zadnje mužnje.
The difference between groups was 8.7% (95% confidence interval 4.9-12.6%).
Razlika između skupina bila je 8,7% (95% interval pouzdanosti; 4,9-12,6%).
The product should only be used in dairy cows at the time of drying-off.
Proizvod treba primjenjivati samo u muznih krava u vrijeme zasušivanja.
Disposal: read package leaflet
Odlaganje: Pročitati uputu o VMP
This was confirmed in another multicentric randomized clinical trial where incidence of milk leakage was significantly lower among Velactis treated animals (3.9%) as compared to placebo treated animals (17.6%).
To je potvrđeno u još jednom multicentričnom randomiziranom kliničkom ispitivanju u kojem je učestalost curenja mlijeka bila značajno niža u životinja liječenih Velactisom (3,9%) u usporedbi sa životinjama liječenim placebom (17,6%).
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
6.6 Posebne mjere prilikom odlaganja neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tog proizvoda Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s propisima o zbrinjavanju otpada.
Therefore, the product should only be administered to dairy cows at the time of drying-off.
Zato proizvod treba primjenjivati samo u muznih krava u vrijeme zasušivanja.
The efficacy of Velactis in reducing the risk of new intramammary infections during the dry period when administered concomitantly with antimicrobial treatment to cows with intramammary infections has not been investigated compared to antimicrobial treatment alone.
Djelotvornost primjene Velactisa zajedno s antimikrobnim liječenjem u usporedbi s primjenom samo antimikrobnog liječenja za smanjenje rizika od novih intramamarnih infekcija tijekom suhostaja kod krava s intramamarnim infekcijama nije istraživana.
In case of accidental self-injection, seek medical advice, and show this package leaflet or the label to the physician.
U slučaju da se nehotice samoinjicira, potražite pomoć liječnika i pokažite mu ovu uputu o VMP ili etiketu.
CONTRAINDICATIONS Do not use in case of hypersensitivity to cabergoline or to any of the excipients.
KONTRAINDIKACIJE Ne primjenjivati u slučaju preosjetljivosti na kabergolin ili na bilo koju od pomoćnih tvari.
Slight injection site reactions (mostly swellings) were commonly observed after injection of the product and may persist for at least 7 days.
Nakon injiciranja lijeka često su zapažene blage reakcije na mjestu primjene (uglavnom oticanje) koje mogu potrajati najmanje 7 dana.
Cardboard box of 5 ml vial Cardboard box of 25 ml vial Cardboard box of 50 ml vial Cardboard box of 5x5 ml vials
Kartonska kutija s bočicom od 5 ml Kartonska kutija s bočicom od 25 ml Kartonska kutija s bočicom od 50 ml Kartonska kutija s 5 bočica od 5 ml
The difference in percentage of new intramammary infections during the dry period between Velactis treated animals and the placebo group was 5.5% (95% confidence interval 0.5-10.4%).
Razlika u postotku novih intramamarnih infekcija tijekom suhostaja između skupina životinja liječenih Velactisom i placebom bila je 5,5% (95% interval pouzdanosti; 0,5-10,4%).
However, administration of tylosin concomitantly with Velactis in cows did not show any changes of Velactis pharmacokinetic properties.
Ipak, primjena tilozina zajedno s Velactisom nije pokazala nikakve promjene farmakokinetičkih svojstava Velactisa.
WITHDRAWAL PERIOD Withdrawal period: See box
KARENCIJA Karencija: Vidjeti kutiju
Do not use in case of hypersensitivity to cabergoline or to any of the excipients.
Ne primjenjivati u slučaju preosjetljivosti na kabergolin ili na bilo koju od pomoćnih tvari.
In case of accidental self-injection, seek medical advice, and show the package leaflet or the label to the physician.
U slučaju da se nehotice samoinjicira, potražite pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
However, administration of tylosin concomitantly with Velactis in cows did not show any changes of cabergoline pharmacokinetic properties.
Ipak, primjena tilozina zajedno s Velactisom nije pokazala nikakve promjene farmakokinetičkih svojstava kabergolina.
Dimethyl sulfoxide Triglycerides, medium-chain
6.1 Popis pomoćnih tvari dimetilsulfoksid srednjelančani trigliceridi
METHOD AND ROUTE(S) OF ADMINISTRATION Intramuscular use
NAČIN I PUT(EVI) PRIMJENE Intramuskularna primjena.
The difference in occurrence of pain was 9.9% (95% confidence interval 4-15.8%) between the Velactis treated cows compared to placebo treated animals.
Razlika u pojavi boli bila je 9,9% (95% interval pouzdanosti; 4-15,8%) između krava liječenih Velactisom i životinja liječenih placebom.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES 1 ml contains 1.12 mg of cabergoline.
I DRUGIH TVARI 1 ml sadržava 1,12 mg kabergolina.
The difference in occurrence of pain was 9.9% (95% confidence interval 4.0-15.8%) between the Velactis treated cows compared to placebo treated animals.
Razlika u pojavi boli bila je 9,9% (95% interval pouzdanosti; 4,0-15,8%) između krava liječenih Velactisom i životinja liječenih placebom.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Label of 5 ml vial
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKOVANJIMA
For cows considered likely to be free of subclinical mastitis at drying off, in which antibiotic use is not justified/permitted, Velactis can be used as a dry cow treatment.
Velactis se može primijeniti kao terapija za zasušivanje krava za koje se smatra da u vrijeme zasušivanja nemaju subklinički mastitis, u kojih primjena antibiotika nije opravdana/dopuštena.
Use during pregnancy, lactation or lay
Primjena tijekom graviditeta, laktacije ili nesenja Može se primjenjivati tijekom graviditeta.
Label of 25 ml vial
Etiketa za bočicu od 25 ml
Cabergoline Bovine 0.10 µg/kg 0.25 µg/kg
0,25 µg/kg 0,50 µg/kg 0,15 µg/kg 0,10 µg/kg masno tkivo jetra bubreg mišić mlijeko
Due to its pharmacological effect (inhibition of lactation) breastfeeding women should avoid contact with the product.
Žene koje doje trebaju izbjegavati doticaj s proizvodom zbog njegovog farmakološkog djelovanja (inhibicije laktacije).
Label of 50 ml vial
Etiketa za bočicu od 50 ml
NO ENTRY
NEMA ZAPISA
PACKAGE LEAFLET FOR Velactis 1.12 mg/ml solution for injection for cattle.
UPUTA O VMP ZA Velactis 1,12 mg/ml otopina za injekciju za goveda
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection for cattle
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju za goveda
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection cabergoline
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju kabergolin
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection for cattle (dairy cows).
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju za goveda (muzne krave). kabergolin
The full EPAR for Emend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Cjeloviti EPAR za lijek Emend nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Emend on 11 November 2003.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Emend na snazi u Europskoj uniji od 11. studenoga 2003.
Emend is a neurokinin 1 (NK1) receptor antagonist.
Emend je antagonist receptora neurokinina 1 (NK1).
• pimozide (used to treat mental illness);
• pimozid (upotrebljava se za liječenje mentalnih bolesti);
Emend 80 mg and 125 mg must not be taken with the following medicines:
Emend 80 i 125 mg ne smije se uzimati sa sljedećim lijekovima:
After chemotherapy, one 80 mg capsule is taken each day for the next two days.
Nakon kemoterapije jedna kapsula od 80 mg uzima se svaki dan sljedeća dva dana.
In the chemotherapy studies in adults, adding Emend to the standard combination was more effective than the standard combination alone.
U kemoterapijskim ispitivanjima provedenima među odraslima dodavanje lijeka Emend standardnoj kombinaciji bilo je učinkovitije od same standardne kombinacije.
• cisapride (used to relieve certain stomach problems).
• cisaprid (koristi se za ublažavanje određenih želučanih problema).
In PONV, Emend was as effective as ondansetron.
Kod PONV-a Emend je bio učinkovit kao i ondansetron.
Other information about Emend
Ostale informacije o lijeku Emend
What measures are being taken to ensure the safe and effective use of Emend?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Emend?
This is nausea and vomiting that a patient can experience after surgery.
Riječ je o mučnini i povraćanju koju bolesnik može iskusiti nakon operacije.
In PONV, two studies were carried out in a total of 1,727 adult patients, most of whom were women undergoing gynaecological operations.
U pogledu PONV-a provedena su dva ispitivanja na ukupno 1 727 odraslih bolesnika, većinom žena koje su bile podvrgnute ginekološkim operacijama.
The dose of Emend oral suspension to be given depends on the patient's bodyweight.
Doza oralne suspenzije Emend daje se ovisno o tjelesnoj težini bolesnika.
It stops a chemical in the body (substance P) from binding to the NK1 receptors.
Sprečava vezanje kemijske tvari u tijelu (tvar P) na receptore NK1.
• terfenadine, astemizole (commonly used to treat allergy symptoms - these medicines may be available without a prescription);
• terfenadin, astemizol (često se primjenjuju za liječenje alergijskih simptoma - ti se lijekovi mogu izdavati i bez liječničkog recepta);
Emend was also shown to be effective in the first 24 hours after chemotherapy.
Emend se pokazao učinkovitim i u prva 24 sata nakon kemoterapije.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Emend.
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Emend.
In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5HT3 antagonist.
U djece u dobi od 6 mjeseci do 12 godina oralna suspenzija Emend daje se zajedno s antagonistom 5HT3.
This is a summary of the European public assessment report (EPAR) for Emend.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Emend.
For more information about treatment with Emend, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Emend pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
Emend is a medicine containing the active substance aprepitant.
Emend je lijek koji sadrži djelatnu tvar aprepitant.
Emend 40 mg capsules are used to prevent postoperative nausea and vomiting (PONV) in adults.
Kapsule Emenda od 40 mg upotrebljavaju se za sprečavanje postoperativne mučnine i povraćanja (PONV) u odraslih.
Why has Emend been approved?
Zašto je Emend odobren?
A risk management plan has been developed to ensure that Emend is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Emend.
The most common side effect of Emend at all doses in adults (seen in between 1 and 10 patients in 100) is increased liver enzymes.
Najčešće su nuspojave lijeka Emend pri svim dozama za odrasle (mogu se javiti u 1 do 10 bolesnika na 100) povišeni jetreni enzimi.
The first two studies involved a total of 1,094 adults receiving chemotherapy including cisplatin, and the third involved 866 adults with breast cancer who were receiving cyclophosphamide, with or without doxorubicin or epirubicin.
U prva dva ispitivanja sudjelovalo je ukupno 1 094 odraslih koji su primali kemoterapiju uključujući cisplatin, a u trećemu je sudjelovalo 866 odraslih osoba koje boluju od raka dojke, a primali su ciklofosfamid, s doksorubicinom ili epirubicinom ili bez njih.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Emend, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Emend nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
All three studies compared the effectiveness of Emend, taken in combination with dexamethasone and ondansetron, with that of the standard combination of dexamethasone and ondansetron.
U sva tri ispitivanja uspoređivala se učinkovitost lijeka Emend, koji se uzima u kombinaciji s deksametazonom i ondansetronom, sa standardnom kombinacijom deksametazona i ondansetrona.
The main measure of effectiveness was the number of patients who had no nausea and vomiting in the five days after receiving chemotherapy.
Glavna je mjera učinkovitosti bio broj bolesnika koji nisu osjećali mučninu ili nisu povraćali pet dana nakon primanja kemoterapije.
The CHMP decided that Emend's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je odlučio da koristi od lijeka Emend nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje u promet.
It is only given on the first day of the chemotherapy and is followed by treatment involving a corticosteroid and a 5HT3 antagonist.
Daje se samo prvoga dana kemoterapije, a nakon njega slijedi liječenje koje uključuje kortikosteroid i antagonist 5HT3.
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting.
Emend je antiemetik, lijek koji sprečava mučninu (osjećaj slabosti) i povraćanje.
It must be given with other medicines that also prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5-HT3 antagonist' (such as ondansetron).
Mora se davati s drugim lijekovima koji također sprečavaju mučninu i povraćanje, uključujući kortikosteroid (kao što je deksametazon) i „antagonist 5HT3” (kao što je ondansetron).
Emend 165 mg is given to adults only once, one hour before the start of chemotherapy.
Emend 165 mg daje se odraslima samo jedanput, jedan sat prije početka kemoterapije.
Emend is used with other medicines to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
Emend se upotrebljava s drugim lijekovima za sprečavanje mučnine i povraćanja uzrokovanih kemoterapijom (lijekovi koji se upotrebljavaju za liječenje raka).
What is the risk associated with Emend?
Koji su rizici povezani s lijekom Emend?
By blocking the receptors, Emend can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery.
Blokirajući receptore, Emend može spriječiti mučninu i povraćanje, koji se često javljaju nakon kemoterapije ili kao postoperativna komplikacija.
In chemotherapy, three main studies have been carried out for Emend 80 and 125 mg capsules.
U pogledu kemoterapije provedena su tri glavna ispitivanja kapsula Emenda od 80 i 125 mg.
It is used with chemotherapy that is a moderate or high trigger of nausea and vomiting such as cisplatin, cyclophosphamide, doxorubicin or epirubicin.
Upotrebljava se uz kemoterapiju koja uzrokuje umjerenu do snažnu mučninu i povraćanje, kao što su cisplatin, ciklofosfamid, doksorubicin ili epirubicin.
In PONV, the usual dose is one 40 mg capsule given to adults within the three hours before the patient is anaesthetised (‘put to sleep').
Kod PONV-a uobičajena je doza jedna kapsula od 40 mg koja se odraslima daje tri sata prije anesteziranja („uspavljivanja”) bolesnika.
It is available as capsules (40, 80, 125 and 165 mg) and as a powder to be made up into an oral (by mouth) suspension (125 mg).
Dostupan je u kapsulama (40, 80, 125 i 165 mg) i u prahu za pripravljanje oralne (na usta) suspenzije (125 mg).
The effectiveness of Emend was also seen during a further five cycles of chemotherapy.
Učinkovitost lijeka Emend zabilježena je i tijekom sljedećih pet ciklusa kemoterapije.
Emend oral suspension is given one hour before the start of chemotherapy, and for the next 2 days.
Oralna suspenzija Emend daje se jedan sat prije početka kemoterapije te sljedeća dva dana.
The studies measured how many patients had a complete response, which was defined as no vomiting and no need for any other medication to control nausea and vomiting in the 24 hours after the operation.
U ispitivanjima se mjerilo koliko je bolesnika imalo potpunu reakciju, koja se definirala kao izostanak povraćanja te potrebe za drugim lijekovima za kontrolu mučnine i povraćanja tijekom 24 sata nakon operacije.
What is Emend?
Što je Emend?
Tests were performed to determine that Emend 165 mg produces the same amount of aprepitant in the body as a single dose of 150 mg Ivemend.
Obavljeno je testiranje kako bi se utvrdilo proizvodi li Emend 165 mg jednaku količinu aprepitanta u tijelu kao jedna doza lijeka Ivemend od 150 mg.
A fourth study has been carried out with Emend (125 mg capsules or 125 mg oral solution) in 307 children from 6 months to 17 years of age, where Emend, taken with ondansetron (with or without dexamethasone), was compared with ondansetron alone (with or without dexamethasone).
Četvrto ispitivanje lijeka Emend (kapsule od 125 mg ili otopina za oralnu primjenu od 125 mg) provedeno je na uzorku od 307 djece u dobi od 6 mjeseci do 17 godina, gdje se Emend, primijenjen uz ondansetron (s deksametazonom ili bez njega), uspoređivao s primjenom samoga ondansetrona (s deksametazonom ili bez njega).
Emend 80, 125 and 165 mg capsules are used in adults; children from 12 years of age may be given the 80- or 125-mg capsules and children between 6 months and 12 years of age are given the oral suspension.
Kapsule lijeka Emend od 80, 125 i 165 mg upotrebljavaju se u odraslih; djeci starijoj od 12 godina mogu se dati kapsule od 80 ili 125 mg, a djeci od 6 mjeseci do 12 godina starosti daje se oralna suspenzija.
Two doses of Emend (40 and 125 mg as capsules) were compared with ondansetron given as an injection.
Dvije doze lijeka Emend (kapsule od 40 i 125 mg) uspoređene su s ondansetronom koji se daje kao injekcija.
At a dose of 80, 125 and 165 mg, the other side effects seen in between 1 and 10 patients in 100 are headache, hiccups, constipation, dyspepsia (indigestion), loss of appetite, and fatigue (tiredness).
Pri dozi od 80, 125 i 165 mg ostale nuspojave koje se mogu javiti u 1 do 10 bolesnika na 100 jesu sljedeće: glavobolja, štucanje, zatvor, dispepsija (žgaravica), gubitak apetita te iscrpljenost (umor).
In chemotherapy, the usual dose of Emend in adults and children from 12 years of age is one 125 mg capsule by mouth one hour before the start of chemotherapy.
Tijekom kemoterapije uobičajena je doza lijeka Emend u odraslih i djece starije od 12 godina jedna kapsula od 125 mg oralno jedan sat prije početka kemoterapije.
In the study in children, around 51% (77 out of 152) of children given Emend with ondansetron had a complete response 25 to 120 hours after beginning chemotherapy, compared with 26% (39 out of 150) of children given ondansetron alone.
U ispitivanju provedenome među djecom, u otprilike 51% (77 od 152) djece koja su primala Emend s ondansetronom zabilježena je potpuna reakcija 25 do 120 sati nakon početka kemoterapije, u usporedbi s 26% (39 od 150) djece koja su primala samo ondansetron.
Emend 165 mg capsules were shown to be bioequivalent to Ivemend 150 mg, which means that like Ivemend it can also be used to prevent nausea and vomiting caused by chemotherapy.
Utvrđeno je da su kapsule lijeka Emend od 165 mg bioekvivalentne kapsulama lijeka Ivemend od 150 mg, što znači da se, baš kao i Ivemend, može upotrebljavati za sprečavanje mučnine i povraćanja uzrokovanih kemoterapijom.
Emend makes chemotherapy more tolerable for the patient.
Emend bolesniku olakšava podnošenje kemoterapije.
What is Emend used for?
Za što se Emend koristi?